Literature DB >> 14531547

MIB-1 immunoreactivity in craniopharyngiomas: a clinico-pathological analysis.

D Duò1, S Gasverde, F Benech, F Zenga, M T Giordana.   

Abstract

BACKGROUND: Craniopharyngiomas are epithelial tumors of the suprasellar region, unanimously defined as benign. Despite the benign histological aspect and apparent gross total resection achieved in a proportion of cases, recurrence rate remains about 30% at 10 years. The role of 7 pathological factors as predictors of recurrence and clinical outcome in craniopharyngioma patients is controversial, as well as the prognostic role of the evaluation of proliferation potential.
MATERIAL AND METHODS: In the present study, the proliferation potential of 37 craniopharyngiomas was investigated by analyzing the pattern of Ki-67-MIBI immunoreactivity; the data have been analyzed in relation to age of the patient, histologic type (adamantinomatous/squamous papillary), microscopic and cytochemical features.
RESULTS: Craniopharyngiomas operated in adults have a higher MIB-1-LI than those of children; the epithelial cells abutting the stromal cysts are engaged in the cell cycle, while this is not the case for the cells abutting the nervous tissue; MIB-1-LIs of adamantinomatous craniopharyngiomas are not different from those of squamous papillary craniopharyngiomas, the localization of MIB-1-positive nuclei is different in the 2 craniopharyngioma types, non-epithelial cells proliferate in the stromal component of craniopharyngiomas.
CONCLUSIONS: By analyzing these data while considering all available information on the efficacy of surgery and radiotherapy, the proliferation potential of craniopharyngiomas, when evaluated by MIB-1, has no role in the outcome. The very low MIB-1-LI of the intracerebral tumor growth indicates that uncompletely resected tumor remnants do not represent an active starting point of recurrence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531547

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  12 in total

1.  Expression of matrix metalloproteinase-9, type IV collagen and vascular endothelial growth factor in adamantinous craniopharyngioma.

Authors:  Zhiqiang Xia; Wenqing Liu; Shengdong Li; Ge Jia; Yuqi Zhang; Chunde Li; Zhenyu Ma; Jihui Tian; Jian Gong
Journal:  Neurochem Res       Date:  2011-08-04       Impact factor: 3.996

2.  Angiogenesis and the growth potential of craniopharyngiomas.

Authors:  Sergio Vidal; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 3.  A Practical Approach to the Differential Diagnosis of Intracranial Tumors: Gross, Histology, and Immunoprofile-based Algorithm.

Authors:  George S Stoyanov; Lilyana Petkova; Deyan L Dzhenkov
Journal:  Cureus       Date:  2019-12-15

Review 4.  Histopathological and molecular predictors of growth patterns and recurrence in craniopharyngiomas: a systematic review.

Authors:  Josephine R Coury; Brittany N Davis; Christoforos P Koumas; Giovanna S Manzano; Amir R Dehdashti
Journal:  Neurosurg Rev       Date:  2018-04-17       Impact factor: 3.042

Review 5.  Ectopic recurrence of craniopharyngioma: a case report and review of the literature.

Authors:  In-Ho Jeong; Jung-Kil Lee; Kyung-Sub Moon; Sung-Pil Joo; Hyung-Jun Kwak; Tae-Sun Kim; Jae-Hyoo Kim; Soo-Han Kim
Journal:  J Neurooncol       Date:  2006-07-19       Impact factor: 4.130

Review 6.  Congenital craniopharyngioma treated by radical surgery: case report and review of the literature.

Authors:  Teruyoshi Kageji; Takeshi Miyamoto; Yumiko Kotani; Tsuyoshi Kaji; Yoshimi Bando; Yoshifumi Mizobuchi; Kohei Nakajima; Shinji Nagahiro
Journal:  Childs Nerv Syst       Date:  2016-09-26       Impact factor: 1.475

7.  The cell-cycle kinetics of craniopharyngioma and its clinical significance.

Authors:  Jianguo Xu; Chao You; Liangxue Zhou; Qiang Li; Peizhi Zhou; Ni Chen
Journal:  J Neurooncol       Date:  2009-11-24       Impact factor: 4.130

8.  Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas.

Authors:  D F Ierardi; M J S Fernandes; I R Silva; J Thomazini-Gouveia; N S Silva; P Dastoli; S R C Toledo; S Cavalheiro
Journal:  Childs Nerv Syst       Date:  2007-06-26       Impact factor: 1.475

9.  Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor.

Authors:  Jianguo Xu; Sizhong Zhang; Chao You; Siqing Huang; Bowen Cai; Xiaojie Wang
Journal:  J Neurooncol       Date:  2007-04-05       Impact factor: 4.506

Review 10.  Association of histological subtype with risk of recurrence in craniopharyngioma patients: a systematic review and meta-analysis.

Authors:  Jie Wu; Xiao Wu; You Qing Yang; Han Ding; Le Yang; You Yuan Bao; Lin Zhou; Chen Xing Yang; Tao Hong
Journal:  Neurosurg Rev       Date:  2021-06-22       Impact factor: 2.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.